Abstract 140: Significant reduction in HbA1c levels among participants with poorly controlled type 2 diabetes on diabefly® digital therapeutics program using multidisciplinary approach

Background: Long-term hyperglycemia is a potential risk factor for both macro and microvascular complications in Type 2 diabetes. Digital therapeutics platform can be a highly accessible and cost-effective way in helping these patients with dietary, behavior change and fitness advice aimed towards better glycemic control. Aims and Objectives: To evaluate the effectiveness of Diabefly ® digital therapeutics program using multidisciplinary approach in participants with type 2 diabetes mellitus having HbA1c ≥9%. Results: De-identified data of 49 participants using Diabefly ® platform was analysed. The mean age was 46.12 years and 57.14% were females. At the end of 90 days, a significant mean reduction in HbA1C, body weight and body mass index (BMI) by 3.34%, 2.41 kg and 0.82 kg/m 2 ( p